Liverpool are on the verge of signing Eintracht Frankfurt centre-forward Hugo Ekitiké (23) in a €90m deal. L'Equipe has ...

There are all these drugs available, sitting in your local pharmacy, but they aren’t being used to treat all the conditions ...

There’s a certain kind of silence that falls on a room the moment you mention network marketing in Uganda. It’s the kind of ...

Obesity, a complex health issue, isn't solely due to inactivity, a study in PNAS reveals. Researchers found similar calorie ...

Research by Takebe et al. demonstrated that vascularised liver organoids derived from induced pluripotent stem cells (iPSCs) ...

Singaporean researchers have unveiled a new artificial intelligence-based scoring tool designed to predict the recurrence of ...

Discover a study validating the TRIUMPH machine learning model, which improves prediction of post-transplant recurrence in ...

Liver organoids with proper blood vessel networks have been successfully produced, as reported by researchers from Institute ...

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment ...

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment.